Skip to main
SYRE

SYRE Stock Forecast & Price Target

SYRE Analyst Ratings

Based on 13 analyst ratings
Strong Buy
Strong Buy 62%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Spyre Therapeutics is well-positioned for long-term success in the treatment of immune-based diseases such as inflammatory bowel disease and rheumatoid arthritis, as evidenced by positive clinical trial results and a strong pipeline. The company's YTE half-life extension technology is a key differentiator, potentially leading to improved efficacy and convenience in comparison to competitors' therapies. With an expanded focus on rheumatology and dermatology, as well as potential combination therapies, Spyre has ample opportunities for commercial success and could emerge as a leader in the market. Additionally, the company's clean safety profile and potential for accelerated regulatory approval are positive indicators for future growth.

Bears say

Spyre Therapeutics is facing several challenges, including a lack of near-term catalysts, potential difficulties with ad hoc co-formulation of their drugs, and disappointing results for their SPY072 monotherapy in rheumatoid arthritis. Additionally, while their extended half-life antibody, SPY003, has shown potential in ulcerative colitis, other competitors may have more advanced and/or superior treatments. This, coupled with the company's lack of revenue and limited pipeline, leads to a negative outlook on the stock.

SYRE has been analyzed by 13 analysts, with a consensus rating of Strong Buy. 62% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Spyre Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Spyre Therapeutics Inc (SYRE) Forecast

Analysts have given SYRE a Strong Buy based on their latest research and market trends.

According to 13 analysts, SYRE has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $107.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $107.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Spyre Therapeutics Inc (SYRE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.